We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-0.2%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$279M
AUM Growth
-$15.1M
Cap. Flow
-$10.5M
Cap. Flow %
-3.76%
Top 10 Hldgs %
54.03%
Holding
87
New
14
Increased
26
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$4.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.48M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$3.39M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$2.97M
5
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$2.93M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$5.49M
2
CRIS icon
Curis
CRIS
+$3.95M
3
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$2.96M
4
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$2.54M
5
CLDX icon
Celldex Therapeutics
CLDX
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 67.7%
2 Financials 3.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$16.7B
$2.63M 0.94%
20,000
– –
IOVA icon
27
Iovance Biotherapeutics
IOVA
$2.23B
$2.6M 0.93%
100,000
+75,400
+307% +$1.96M
HZNP
28
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.34M 0.84%
25,000
-10,000
-29% -$920K
ALDX icon
29
Aldeyra Therapeutics
ALDX
$91.7M
$2.27M 0.81%
200,000
-100,000
-33% -$1.2M
BGMS
30
Bio Green Med Solution Inc
BGMS
$5.05M
$2.25M 0.81%
106
– –
MGNX icon
31
MacroGenics
MGNX
$235M
$2.15M 0.77%
80,000
+55,000
+220% +$1.61M
MREO
32
Mereo BioPharma
MREO
$45.9M
$2.06M 0.74%
650,000
-250,000
-28% -$839K
SWTX
33
DELISTED
SpringWorks Therapeutics
SWTX
$2.06M 0.74%
25,000
-2,000
-7% -$152K
EPIX
34
DELISTED
ESSA Pharma
EPIX
$2M 0.72%
70,000
-20,000
-22% -$581K
SDGR icon
35
Schrodinger
SDGR
$1.12B
$1.89M 0.68%
+25,000
New +$1.81M
ESTA icon
36
Establishment Labs
ESTA
$2.72B
$1.75M 0.63%
20,000
+10,000
+100% +$744K
AXSM icon
37
Axsome Therapeutics
AXSM
$12.4B
$1.69M 0.6%
25,000
+15,000
+150% +$900K
CLDX icon
38
Celldex Therapeutics
CLDX
$2.77B
$1.67M 0.6%
50,000
-80,000
-62% -$2.2M
NTLA icon
39
Intellia Therapeutics
NTLA
$1.5B
$1.62M 0.58%
+10,000
New +$779K
SNCE
40
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.5M 0.54%
7,500
-12,500
-63% -$2.54M
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$1.49M 0.53%
+66,957
New +$1.57M
BFLY icon
42
Butterfly Network
BFLY
$1.72B
$1.45M 0.52%
100,000
– –
LKFT
43
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$1.39M 0.5%
20,000
+7,500
+60% +$572K
CYTK icon
44
Cytokinetics
CYTK
$11B
$1.39M 0.5%
70,000
+30,000
+75% +$704K
AFIB
45
DELISTED
Acutus Medical Inc
AFIB
$1.36M 0.49%
80,000
+20,000
+33% +$293K
KALV
46
DELISTED
KalVista Pharmaceuticals
KALV
$1.2M 0.43%
50,000
-50,000
-50% -$1.31M
CGEM icon
47
Cullinan Oncology
CGEM
$1.05B
$1.16M 0.41%
+45,000
New +$1.38M
MRSN
48
DELISTED
Mersana Therapeutics
MRSN
$1.15M 0.41%
3,400
– –
TNGX icon
49
Tango Therapeutics
TNGX
$4.34B
$1.14M 0.41%
100,000
– –
PCVX icon
50
Vaxcyte
PCVX
$7.89B
$1.13M 0.4%
50,000
+20,000
+67% +$409K
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Affinity Asset Advisors held 87 positions worth $279M, down 5.1% from $294M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Affinity Asset Advisors withdrew a net $10.5M in Q2 2021, closing 18 positions and reducing 16 holdings. Its most notable exit was Travere Therapeutics, an estimated $5.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Medicus Sciences Acquisition Corp. Class A Ordinary Share worth $2.9M.

  • Affinity Asset Advisors's largest Q2 2021 buy was Medicus Sciences Acquisition Corp. Class A Ordinary Share: 300,000 shares worth $2.9M.
  • Affinity Asset Advisors added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $4.5M increase.
  • Affinity Asset Advisors's biggest Q2 2021 reduction was Curis, cutting an estimated $3.95M.
  • Affinity Asset Advisors fully exited Travere Therapeutics in Q2 2021, selling an estimated $5.49M.
  • Affinity Asset Advisors's ten largest holdings make up 54% of its $279M portfolio in Q2 2021.
  • Affinity Asset Advisors opened 14 new positions and closed 18 in Q2 2021.
  • Affinity Asset Advisors's portfolio value fell 5.1% quarter-over-quarter to $279M.

Based on Affinity Asset Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.